• Bangalore
  • 11 December 2012
  • Features
  • By Rahul Koul

Sweet tooth alternative for diabetics

Utilizing the funding from DBT, GVS Biotech has initiated a unique project to produce zero-calorie natural sweeteners from the leaves of Stevia plant


With continuous increase in diabetes cases, India is slowly being recognized as a diabetic capital of the world. As a result of which, we have a huge chunk of health conscious diabetic population looking for a product that could be harmlessly sweet for them to consume. It is thus the need of the hour to have a zero-calorie natural sweetener. Since the plant Stevia rebaudiana is known to produce such sweeteners from its leaves, the hopes of having an indigenous natural product have significanly gone high.

Nawanshahr (Punjab) based GVS Biotech initiated the project to provide an alternative in the form of a chemical-free product from sweeteners extracted from Stevia leaves. The aim was to make a product which would satisfy the sweet tooth of the people while keeping them safe from diabetes. The project that was initiated in mid 2011 has reached a critical stage and is fast approaching the product stage. The company received the much required funding of about 50 percent of the project as soft loan by Department of Biotechnology (DBT) under Small Business Innovation Research Initiative (SBIRI) scheme.

With its steviol glycoside extracts having up to 300 times the sweetness of sugar, Stevia plant has garnered attention with the rise in demand for low-carbohydrate, low-sugar food alternatives. Because Stevia has a negligible effect on blood glucose, it is attractive as a natural sweetener to people on carbohydrate-controlled diets.

Citing the global scenario, Mr RPS Gandhi, chairman and managing director, GVS Biotech, said, "China, which is leading in the Stevia field, has been working on it for the last two decades. USFDA has already approved this product as sweetener besides many other countries like Australia, Canada, Europe, Japan, and New Zealand. We are keen on entering into the Indian market, otherwise India will always be an importer of this product, rather than being a producer or exporter. In fact, it could be the start of sweet revolution in India."

Way forward


Previous 1 Next
2 Comment Comment 1 - 1 of 1

OPschool 28 February 2013 at 06:44 AM

Agreed Mark, a global frzeee out of pharma's efforts in social media would be detrimental to the industry. The optimist in me would like to think that developments such as Sidewiki will force the hand of pharma to develop a social media strategy. After all, Sidewiki is one of the first social media tools that leaves companies no choice, the conversation is in their backyard. However, the realist in me understands that this is not the typical course of action for Big Pharma. Look no further than the industry's response to a few wrist slaps around search advertising. Ads plummeted for fear of further sanctions. Hopefully the FDA will keep the lines of communications open as this guidance is established and help to avoid the frzeee out.


Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email